文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATATE PET 用于表征神经轴病变

68 Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis.
PubMed 文献 · Clin Nucl Med · 2023-12-01

回顾性研究纳入 52 例患者的 70 个神经轴病变,评估 68Ga-DOTATATE PET/CT 在常规 MRI 不能确诊时鉴别头颈部副神经节瘤、神经鞘瘤、脑膜瘤等的作用;副神经节瘤摄取显著高于非副神经节瘤,神经鞘瘤摄取近零,脑膜瘤呈中等摄取。

要点

  • 副神经节瘤 68Ga-DOTATATE 摄取明显高于非副神经节瘤,但个体间变异大。
  • 神经鞘瘤 68Ga-DOTATATE 摄取近零,低至中等摄取基本可排除神经鞘瘤。
  • SUVmax>50 倾向副神经节瘤诊断,低至中等摄取对多种神经轴肿瘤无特异性。

核心结论

  • 明显 68Ga-DOTATATE 摄取(SUVmax>50)倾向副神经节瘤诊断,但副神经节瘤摄取变异大。
  • 低至中等 68Ga-DOTATATE 摄取无特异性,可能代表副神经节瘤、脑膜瘤及其他神经轴肿瘤等多种病理,但基本排除神经鞘瘤,后者几乎无摄取。

研究设计与样本

  • 回顾性研究,纳入 52 例患者的 70 个神经轴病变,均行 68Ga-DOTATATE PET/CT 检查,其中 22 个病变(31%)有病理证实。
  • 病变依据病理诊断分组,无病理时依据最佳影像学诊断分组;采用 Wilcoxon 秩和检验比较副神经节瘤、神经鞘瘤和脑膜瘤的 SUVmax,并构建受试者工作特征曲线。

主要发现

  • 副神经节瘤 68Ga-DOTATATE 摄取显著高于非副神经节瘤,中位 SUVmax 为 62(四分位距 89)。
  • 神经鞘瘤 68Ga-DOTATATE 摄取近零,中位 SUVmax 为 2(四分位距 1)。
  • 脑膜瘤呈中等 68Ga-DOTATATE 摄取,中位 SUVmax 为 19(四分位距 6);其他神经轴病变中位 SUVmax 为 7(四分位距 9)。
  • 受试者工作特征分析显示,副神经节瘤对比所有其他病变的曲线下面积为 0.87,神经鞘瘤对比所有其他病变的曲线下面积为 0.97。

关键数值与推荐

  • 副神经节瘤中位 SUVmax 62(IQR 89)vs 非副神经节瘤,副神经节瘤显著更高。
  • 神经鞘瘤中位 SUVmax 2(IQR 1),脑膜瘤中位 SUVmax 19(IQR 6),其他神经轴病变中位 SUVmax 7(IQR 9)。
  • 副神经节瘤对比所有其他病变的 ROC 曲线下面积为 0.87;神经鞘瘤对比所有其他病变的 ROC 曲线下面积为 0.97。
  • SUVmax>50 倾向副神经节瘤诊断。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The differentiation of paragangliomas, schwannomas, meningiomas, and other neuroaxis tumors in the head and neck remains difficult when conventional MRI is inconclusive. This study assesses the utility of 68 Ga-DOTATATE PET/CT as an adjunct to hone the diagnosis. PATIENTS AND METHODS: This retrospective study considered 70 neuroaxis lesions in 52 patients with 68 Ga-DOTATATE PET/CT examinations; 22 lesions (31%) had pathologic confirmation. Lesions were grouped based on pathological diagnosis and best radiologic diagnosis when pathology was not available. Wilcoxon rank sum tests were used to test for differences in SUV max among paragangliomas, schwannomas, and meningiomas. Receiver operator characteristic curves were constructed. RESULTS: Paragangliomas had a significantly greater 68 Ga-DOTATATE uptake (median SUV max , 62; interquartile range [IQR], 89) than nonparagangliomas. Schwannomas had near-zero 68 Ga-DOTATATE uptake (median SUV max , 2; IQR, 1). Intermediate 68 Ga-DOTATATE uptake was seen for meningiomas (median SUV max , 19; IQR, 6) and other neuroaxis lesions (median SUV max , 7; IQR, 9). Receiver operator characteristic analysis demonstrated an area under the curve of 0.87 for paragangliomas versus all other lesions and 0.97 for schwannomas versus all other lesions. CONCLUSIONS: Marked 68 Ga-DOTATATE uptake (>50 SUV max ) favors a diagnosis of paraganglioma, although paragangliomas exhibit a wide variability of uptake. Low to moderate level 68 Ga-DOTATATE uptake is nonspecific and may represent diverse pathophysiology including paraganglioma, meningioma, and other neuroaxis tumors but essentially excludes schwannomas, which exhibited virtually no uptake.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartmann K, Gillman JA, Lazor JW, et al. 68 Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis. Clin Nucl Med. 2023. PMID: 38048554. doi:10.1097/RLU.0000000000004966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。